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Abstract 
Proteoglycans are associated with the initiation of atherosclerosis due to their binding of 
apolipoproteins on lipid particles leading to retention in the vessel wall. The signalling pathways 
through which growth factors regulate the synthesis and structure of proteoglycans are potential 
therapeutic targets. Platelet-derived growth factor (PDGF) is present in atherosclerotic plaques 
and activates phosphorylation of the serine/threonine kinase Akt. We have investigated the role 
of Akt in the signalling pathways for proteoglycan core protein expression and elongation of 
glycosaminoglycan chains on proteoglycans secreted by human vascular smooth muscle cells. 
The pharmacological inhibitor of Akt phosphorylation, SN30978, blocked PDGF stimulated 
phosphorylation of Akt. SN30978 caused concentration dependent inhibition of PDGF 
stimulated radiosulfate incorporation into secreted proteoglycans and the response was blocked 
by the PDGF receptor antagonists Ki11502 and imatinib. Analysis of the size of the biglycan 
molecules by SDS-PAGE showed that PDGF increased the apparent size of biglycan but this 
effect on glycosaminoglycan chain elongation was blocked by Ki11502 but not by SN30978. 
PDGF also stimulated total protein core protein synthesis assessed as 
35
S-methionine/cysteine 
incorporation and specifically the expression of versican mRNA. Both of these responses were 
blocked by SN30978. This data shows that PDGF-stimulated proteoglycan core protein synthesis 
but not glycosaminoglycan chain elongation is mediated via Akt phosphorylation. These data 
identify potential pathways for the development of agents which can pharmacologically regulate 
individual components of the synthesis of proteoglycans. 
Keywords: Platelet-derived growth factor, proteoglycans, GAG hyperelongation, Akt, 
atherosclerosis 
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Introduction 
The underlying pathology of most cardiovascular disease (CVD) is atherosclerosis [1, 2]. 
Atherosclerosis is characterized by a pre-inflammatory stage involving the retention of 
atherogenic lipoproteins by modified proteoglycans (PGs) in the vessel wall[3, 4]. The later 
chronic inflammatory stage involves the accumulation of immunogenic products and the 
formation of atherosclerotic plaques[5] [6]. A human pathology study showed unequivocally that 
deposition of extracellular lipid (LDL) in association with the proteoglycan biglycan, precedes 
the inflammatory response [7, 8].  
Proteoglycans are composite protein carbohydrate molecules expressed throughout the body 
[9]. The glycosaminoglycan (GAG) chains on PGs are heavily sulfated and show avid binding 
for many cationic molecules including apolipoproteins [10]. The synthesis of proteoglycan core 
proteins and GAG chains are distinct independently regulated biochemical processes [11]. 
Hormones and growth factors including transforming growth factor (TGF)-β[12], platelet-
derived growth factor (PDGF)[13], endothelin[14] and thrombin[15] stimulate vascular smooth 
muscle cells (VSMCs) resulting in increased core protein expression and an increase in the size 
of the GAG chains on secreted PGs[12, 13, 15, 16]. Several GAG synthesising enzymes 
CSGalNAcT2 and C4ST-1 were recently demonstrated to be upregulated in an in vivo mouse 
model of atherosclerosis [17]. The signalling pathways for proteoglycan synthesis are potential 
targets for the development of therapeutic agents which prevent proteoglycan-dependent diseases 
including atherosclerosis [18]. We have demonstrated the potential of this approach in a mouse 
model of atherosclerosis using an inhibitor of GAG elongation [14, 19].  
The serine/threonine kinase, Akt, also known as protein kinase B, is growth factor responsive 
and is associated with cell survival in response to insulin-like growth factor-1 [20]. Aberrant Akt 
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signalling is associated with numerous cancers [21]. We recently observed that the pro-
atherogenic growth factor TGF-β mediates its effects on proteoglycan synthesis in VSMCs via 
phosphorylation of the signalling intermediate Akt[6]. Other pro-atherosclerotic growth factors 
such as PDGF can be even more potent activators of Akt phosphorylation. PDGF and TGF-β 
have distinct signalling pathways but with some overlap that can include Akt. We have recently 
demonstrated that TGF-β stimulates Akt phosphorylation in human VSMCs and that this 
pathway is involved in TGF-β stimulated proteoglycan core protein expression but not 
chondroitin sulfate/dermatan sulfate (CS/DS) GAG elongation in these cells[6]. Further, we have 
previously demonstrated that the effect of PDGF on proteoglycan synthesis involves the 
activation of phosphatidylinositol 3-kinase (PI3K) [19] an upstream effector of Akt 
phosphorylation. 
In the current work we have investigated the role of Akt phosphorylation in 
PDGF-stimulated proteoglycan core protein expression and GAG chain hyperelongation 
including assessment of the expression of the relevant genes being versican and chondroitin-4-
sulfotransferase (C4ST-1), respectively in human vascular smooth muscle cells (VSMC). We 
find that PDGF is a highly efficacious mediator of Akt phosphorylation and that pharmacological 
inhibition of Akt phosphorylation is associated with inhibition of proteoglycan core protein 
synthesis for versican but not GAG elongation or the expression of C4ST-1. These data indicate 
the common role of phosphoAkt derived from either PDGF or TGF-β stimulation in the 
activation of proteoglycan core protein synthesis in these cells. These data identify potential 
pathways for the development of agents which can pharmacologically regulate individual 
components of the synthesis of proteoglycans. 
Page 5 
 
Materials and Methods. 
Materials 
Dulbecco’s Modified Eagle Medium (DMEM) was from Invitrogen Corporation, USA. 
Foetal bovine serum (FBS) and penicillin-streptomycin-fungizone solution, PDGF-BB and other 
standard reagents were purchased from Sigma-Aldrich Australia. Sulfur-35 Na2SO4 ([
35
S]-
sulfate) and Trans
35
S-label (
35
S-Met/Cys) were from MP Biomedicals, USA. Cetyl pyridinium 
chloride (CPC) was from Unilab Chemicals and Pharmaceuticals, Mumbai, India. Rainbow [
14
C] 
methylated protein molecular weight markers were from Amersham Pharmacia Biotech, USA. 
Cell Culture 
Human VSMCs from the saphenous vein were isolated and characterised as previously 
described [22]. The Human Ethics Committee at the Alfred Hospital (Melbourne, Australia) 
approved this procedure. 
Quantitation of radiolabel incorporation into proteoglycans 
Quiescent human VSMCs in 24 well plates were treated in 0.5ml 5mM glucose DMEM, 
0.1% FBS, 0.1% DMSO with and without inhibitors as detailed in Results section and exposed to 
35
S-SO4 (50Ci/ml) in the presence of PDGF (50ng/ml) for 24 hours. Secreted proteoglycans 
were harvested and 
35
S-SO4 incorporation into proteoglycans was quantitated using the CPC 
precipitation assay [12, 23, 24]. 
SDS-PAGE analysis of proteoglycan size 
Proteoglycans were sized by SDS-PAGE as described previously [24]. In all instances three 
measurements were performed from three separate experiments with a representative shown. 
SDS-PAGE gels show dotted white line as an estimate of the mid-line of PG or GAG band size. 
Western blots  
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Total cell lysates were resolved on 10% SDS-PAGE and transferred onto PVDF. 
Membranes were blocked with 5% skim milk powder, incubated with antibodies as described 
previously [19]. Primary antibodies used in this study were anti-phosphoAkt (phosphoThr308) 
antibody and anti-GAPDH antibody (Cell Signaling Technology, MA, USA). Secondary 
antibodies were HRP-anti-species specific IgG and were followed by ECL detection 
(Amersham). Blots from three experiments were quantified by densitometry using QuantityOne 
software (BioRad).  
Reverse transcription PCR 
RNA from cultured VSMC cells was extracted using Trizol (Invitrogen, Carlsbad, CA, 
USA) following the manufacturer's protocol and reverse transcription was performed using All-
in-one First-strand cDNA synthesis kit (GeneCopoeia, USA) and Quantitect Reverse 
Transcription Kit (Qiagen). Versican primer sequences primer sequences were: forward 5'- 
GCCGCCTTCCAAGGCCAAGA -3', reverse 5'- GCCCCTCACCGGTGGGCTTT -3'; 
chondroitin-4-sulfotransferase (C4ST-1) primers were: forward 5'- GGCCCTGCGCAAAG -3', 
reverse 5'- GGGTGTGTGGGTCGATGAG -3'. Primers for 18s were purchased from Qiagen 
(Hs_RRN18S_1_SG QuantiTect Primer Assay, Qiagen). The PCR products were examined on 
agarose gels with ethidium bromide staining. 
Statistical analyses 
Data was analysed for statistical significance using a 1-way analysis of variance (ANOVA) 
or a Student’s paired t-test as stated. Results were considered statistically significant at P<0.05 as 
stated. Normalisation of data was performed in some investigations to adjust for control 
variations between individual experiments with data shown as mean  SEM. 
 
Page 7 
 
Results 
We have previously reported that PDGF stimulates the phosphorylation of Akt in human 
VSMCs and that this response is blocked by the specific inhibitor, SN30978 [6]. In the present 
studies we have confirmed this result by showing that PDGF stimulated and SN30978 (2 µM) 
totally inhibited the effect of PDGF on Akt phosphorylation in these cells (Fig. 1). This data 
characterizes SN30978 as an inhibitor of the Akt pathway in these cells. (Fig. 1). We further 
characterized the response as being dependent upon the PDGF receptor and its tyrosine kinase 
activity by utilizing two PDGF receptor antagonists, Ki11502 and imatinib which we have 
previously characterized as PDGF receptor inhibitors in these cells [14, 19]. PDGF stimulated 
phosphorylation of Akt was totally blocked by Ki11502 (300 nM). In preliminary experiments 
with imatinib we used the concentration (1 uM) which we have previously shown to block 
(>95%) phosphorylation of the autophosphorylation site Tyr 857 of the human PDGF receptor β 
[19]. Interestingly, imatinib (1 µM) did not completely block the PDGF stimulation of Akt 
phosphorylation but it was completely blocked by a ten-fold higher concentration (Fig. 1). These 
data confirmed that PDGF treatment of human VSMCs leads to PDGF receptor activation 
followed by downstream phosphorylation of Akt. 
We next assessed the ability of the Akt inhibitor, SN30978, to inhibit PDGF stimulated [
35
S]-
sulfate incorporation into secreted proteoglycans from human VSMCs (Figure 2). VSMCs were 
grown to confluency, serum-deprived for 24 h then stimulated with PDGF and treated with 
pharmacological inhibitors and secreted proteoglycans were quantitated by the CPC precipitation 
method which is specific for the determination of proteoglycans [25, 26]. VSMCs were treated 
for 24 h with PDGF (50 ng/ml) in the presence of SN30978 (30 – 3000 nM) and Ki11502 
(300 nM). PDGF stimulated an approximately two-fold increase in [
35
S]-sulfate incorporation 
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which is consistent with earlier reports [19]. The response to PDGF was blocked in a 
concentration-dependent manner by SN30978 with a half maximally effective inhibitory 
concentration of approximately 500 nM and a maximum response which represented total 
inhibition of the effect of PDGF with no impact on the basal level of [
35
S]-sulfate into 
proteoglycans (Fig. 2). The PDGF inhibitor, Ki11502, also totally blocked the stimulatory effect 
of PDGF on [
35
S]-sulfate incorporation without an appreciable effect on the basal rate of 
incorporation (Fig. 2). 
The major mechanisms through which increased [
35
S]-sulfate incorporation can arise are 
from increased proteoglycan core protein expression (and hence more GAG initiation sites) 
and/or an elongation of the GAG chains on the proteoglycan core proteins [11] an effect which 
usually occurs on all of the family of secreted CS/DS proteoglycans. The changes in average size 
of the proteoglycans can be assessed by SDS-PAGE because the core protein has a defined 
molecular weight and any change in size must result from changes in the size of the GAG chains 
[11]. The predominant small leucine-rich CS/DS proteoglycan synthesized by these cells is 
biglycan [27]. PDGF stimulated an increase in the size of biglycan synthesized and secreted by 
these cells (Fig. 3A, compare lanes 1 and 2) but the GAG elongation effect was not blocked by 
SN30978 (Fig. 3A, lanes 2-7). As expected, Ki11502 (300 nM) inhibited PDGF-stimulated GAG 
elongation (Fig. 3A, lane 2 versus 8). To confirm whether Akt is a signalling intermediate in 
PDGF-mediated GAG synthesis we measured the gene expression level of GAG synthesizing 
enzyme chondroitin-4-sulfotransferase (C4ST-1) in VSMCs (Fig. 3B, 3C). PDGF caused an 
increase in C4ST-1 mRNA expression up to a maximal 2 - 3-fold increase at 6 h (Fig. 3). Pre-
treatment with Akt inhibitor SN30978 had no effect on the PDGF-mediated increase in C4ST-1 
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gene expression at 6 h (Fig. 3C). Together the data clearly demonstrates that Akt is not involved 
in PDGF-stimulated GAG hyperelongation in VSMCs. 
As SN30978 did not block PDGF-stimulated GAG elongation, we assessed if the blockade of 
PDGF-stimulated [
35
S]-sulfate incorporation was due to inhibition of proteoglycan core protein 
expression. We used 
35
S-met/cys labeling and CPC precipitation to quantitate proteoglycan core 
protein expression. PDGF caused a small statistically significant increase in total core protein 
expression and this was blocked in a concentration dependent manner by SN30978 (30 – 3000 
nM) and was totally blocked by Ki11502 (300 nM) (Fig. 4).  
We wanted to examine which specific core protein expression was stimulated by PDGF. In 
these human VSMCs we can detect a small increase in biglycan mRNA in response to TGF-β 
but in accord with the results of others not to PDGF [6, 28]. Although the amount of versican 
produced by human VSMC is very small relative to primate VSMCs, Wight and colleagues have 
demonstrated a marked increase in versican mRNA in response to PDGF [28]. We thus treated 
human VSMCs with PDGF for 0 – 24 h and measured versican mRNA expression levels (Figure 
5A). Peak levels of expression were seen at 24 h of PDGF exposure. In subsequent experiments 
VSMCs were treated with PDGF in the presence of SN30978 and Ki11502 and the level of 
versican mRNA was measured (Fig. 5B). PDGF stimulated a small increase in mRNA for 
versican and the response was blocked by SN30978 and LY294002 (Fig. 5B) an antagonist of 
PI3 kinase upstream of Akt. These data show that PDGF stimulates Akt phosphorylation in 
human VSMCs and that downstream signalling leads to increased proteoglycan core protein 
expression but not GAG elongation.  
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Discussion 
In this paper we show that PDGF is a potent activator of Akt phosphorylation in human 
VSMCs and that PDGF-stimulated proteoglycan core protein synthesis for the CS/DS 
proteoglycan versican is Akt dependent. The stimulation of CS/DS GAG elongation by PDGF 
does not involve Akt phosphorylation. This is similar to the lack of involvement of Akt in 
proteoglycan GAG elongation recently reported for TGF-β [6]. These data reveal both the 
similarities and some of the differences in the signalling pathways that regulate proteoglycan 
synthesis in vascular smooth muscle. In the current work we have identified a growth factor 
signalling intermediate, Akt, which regulates core protein expression but not GAG elongation.  
Of the possible pathways for generating an agent for the prevention of lipid binding and 
retention in the vessel wall and thus atherosclerosis, we are searching for an agent which is a 
specific inhibitor of the GAG elongation response, termed hyperelongation [4, 29]. As 
proteoglycans are ubiquitously expressed and play vital structural roles in many tissues it is 
unlikely that inhibiting core protein expression would provide efficacious, specific and safe 
therapeutic agents. In contrast, many vasoactive compounds present in atherosclerotic vessels 
stimulate elongation of GAG chains and to the extent that longer GAG chains leads to enhanced 
binding to lipoproteins in vitro that in itself may represent a therapeutic target [10, 11, 30]. We 
have shown that the tyrosine kinase inhibitor, imatinib prevents GAG elongation effects and 
enhanced binding in vitro and it also reduces lipid deposition in the vessel wall of high fat fed 
ApoE
-/-
 mice[14, 19]. Imatinib inhibits both the GAG elongation effect of PDGF as well as the 
increased expression of proteoglycan core proteins which is not surprising as we show in the 
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current work that imatinib inhibits PDGF-stimulated Akt phosphorylation which is a key 
pathway in proteoglycan core protein expression. 
One question is how Akt might be involved in the stimulation of proteoglycan, specifically 
versican, core protein expression in these cells. Thus far we are able to make several conclusions 
about the signalling pathways controlling the synthesis of proteoglycans and specifically the 
increased expression of proteoglycan core proteins and GAG elongation. These two parameters 
of proteoglycan synthesis appear to have different signalling pathways - GAG elongation 
involves Mitogen Activated Protein (MAP) kinase, specifically Erk and possibly p38 
phosphorylation[19, 31], whereas the pathways for the increased expression of core proteins 
involve intermediates most closely associated with cell cycle progression such as Akt[6]. Growth 
factor action on tyrosine kinase cell surface receptors leads to activation of PI3K and 
subsequently phosphorylation of Akt as reported here and earlier. Considering examples for 
cancer cells, increased levels of Akt result in negative regulation and a decrease in the level of 
the transcription factor FoxO and the cell cycle dependent factor p27
kip1 
[6, 32]. In the context of 
vascular biology growth factor mediated proliferation involves decreased levels of p27
kip1 
[33]. 
The isoflavone and anti-proliferative agent genistein mediates its inhibitory activity by blocking 
the decrease in p27
kip1
 levels[33]. Genistein also blocks core protein expression but not PDGF-
mediated GAG elongation in VSMCs[28]. We can speculate that the downstream events 
associated with growth factor mediated Akt phosphorylation involve FoxO and p27
kip1
.  
In conclusion, proteoglycans are molecules with key structural and functional roles in tissues 
and studies are demonstrating the plasticity of this quantitatively small but qualitatively critical 
component of the extracellular matrix. Earlier concepts around the static and inert nature of the 
extracellular matrix are being supplanted by studies showing that signalling pathways controlling 
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the structure of proteoglycans are as complex and as interesting as those regulating the cell cycle. 
The serine/threonine kinase Akt is known to be involved in glucose metabolism, cell 
proliferation, apoptosis, transcription and cell migration but we have shown that it is also 
involved in the pathways leading to the synthesis of extracellular matrix. Further research will 
lead to an enhanced understanding of the currently unknown processes that control the synthesis 
of CS/DS GAG chains on proteoglycans and may yield agents which target diseases in which 
proteoglycans are implicated [34, 35].  
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Figure Legends 
Figure 1. An Akt1/2 inhibitor completely blocks PDGF stimulated phosphorylation of Akt 
in human VSMCs. 
Cells were untreated (-) or pre-treated for 30 min with the Akt1/2 inhibitor SN30978 (SN, 2 µM) 
or PDGF inhibitors Ki11502 (Ki, 300 nM) and imatinib (Imat, 1 and 10 uM) and then stimulated 
with PDGF (50 ng/ml) for 1 h.  Cell lysates were processed and probed for phosphoAkt (pAkt) 
and GAPDH as described. 
 
Figure 2. Role of Akt in PDGF-stimulated proteoglycan synthesis in human VSMCs. 
VSMCs were pre-treated for 30 min with SN30978 (0 – 3000 nM) or Ki11502 (300 nM) and 
then stimulated with PDGF (50 ng/ml) for 24 h in the presence of [
35
S]-sulfate. Histogram values 
are expressed as percentage of untreated control value, ## P<0.01 vs control, ** P<0.01 vs 
agonist for 3 independent experiments. 
 
Figure 3. Role of Akt in PDGF-mediated GAG synthesis in human VSMCs. 
(A) VSMCs were pre-treated for 30 min with SN30978 (0 – 3000 nM) or Ki11502 (300 nM) and 
then stimulated with PDGF (50 ng/ml) for 24 h in the presence of [
35
S]-sulfate. SDS-PAGE 
analysis of [
35
S]-sulfate incorporated samples. (B) C4ST-1 mRNA expression in human VSMCs 
after 0, 4, 6, 8 and 10 h of PDGF (50 ng/ml) treatment expressed as fold change over untreated 
control level. Results are shown as the mid-range value of duplicate experiments. (C) C4ST-1 
mRNA expression in VSMCs untreated (-) or pre-treated with SN30978 (SN) for 30 mins 
followed by PDGF treatment for 6 h expressed as fold change over untreated control level.  
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Figure 4. Role of Akt in PDGF-stimulated proteoglycan core protein synthesis in human 
VSMCs. 
VSMCs were pre-treated for 30 min with SN30978 (0 – 3000 nM) or Ki11502 (300 nM) and 
then stimulated with PDGF (50 ng/ml) for 24 h in the presence of [
35
S]-Met/Cys 24 h. Histogram 
values are expressed as percentage of untreated control value, ## P<0.01 vs control, ** P<0.01 
vs agonist. 
 
Figure 5. Pharmacology of the signalling pathway mediating PDGF stimulated versican 
mRNA expression in human VSMCs. 
(A) Confluent serum-deprived human VSMCs were treated with PDGF (50 ng/mL) for the time 
points indicated and the expression of versican mRNA was determined by RT-PCR and 
expressed as fold change over untreated control value. β-Actin expression was used as a loading 
control. (B) VSMCs were treated with PDGF (50 ng/mL) for 24 h after 30 min pre-treatment 
with SN30978 (an Akt inhibitor) or LY294002 (an inhibitor of PI3K). # P<0.05 vs control, * 
P<0.05 vs agonist. 
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